Search
Novartis agreed to acquire London based Myricx Bio today for $1.1B up front and up to $400M in milestones. As Myricx's CEO tells us today at the company's HQ, this is all about novel ADC payloads
CEO Mohit Rawat discusses the deal and the scientific rationale for N-myristoyltransferase inhibitor (NMTi) payloads.
Jul 6
London based Myricx Bio announced a £90M (~$114M) series A financing today, one of the largest in recent years in the UK region
A developer of ADCs today, CEO Robin Carr describes how the company’s N-myristoyltransferase (NMT) payload approach sets them apart.
Jul 8, 2024
.png){kind=logo}